Pasireotide versus octreotide in acromegaly: A head-to-head superiority study

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 3, 2014, Pages 791-799

  Colao, A ^a   Bronstein, M D ^a   Freda, P ^a   Gu, F ^a   Shen, C C ^a   Gadelha, M ^a   Fleseriu, M ^a   Van Der Lely, A J ^a   Farrall, A J ^a   Hermosillo Resendiz K ^a   Ruffin, M ^a   Chen, Y ^a   Sheppard, M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; PASIREOTIDE; SOMATOMEDIN C;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACROMEGALY; ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BACKACHE; CHOLELITHIASIS; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; VERY ELDERLY;

ACROMEGALY; ADENOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; SOMATOSTATIN; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 84895820552     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2480     Document Type: Article

References (27)

1. Arosio M, Reimondo G, Malchiodi E, et al. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol. 2012;167:189-198.
2. Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159:89-95.
3. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol. 2005;152:379-387. (Pubitemid 40439490)
4. Grasso LF, Pivonello R, Colao A. Somatostatin analogs as a first-line treatment in acromegaly: when is it appropriate? Curr Opin Endocrinol Diabetes Obes. 2012;19:288-294.
5. Colao A, Cappabianca P, Caron P, et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin Endocrinol (Oxf). 2009;70:757-768.
6. Melmed S, Cook D, Schopohl J, Goth MI, Lam KS, Marek J. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary. 2010;13:18-28.
7. Mercado M, Borges F, Bouterfa H, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf). 2007;66:859-868. (Pubitemid 47024274)
8. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146:707-716. (Pubitemid 34552506)
9. Petersenn S, Schopohl J, Barkan A, et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, Phase II trial. J Clin Endocrinol Metab. 2010;95:2781-2789.
10. Dietrich H, Hu K, Ruffin M, et al. Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study. Eur J Endocrinol. 2012;166:821-828.
11. Webb SM, Prieto L, Badia X, et al. Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol (Oxf). 2002;57:251-258. (Pubitemid 34989102)
12. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). National Cancer Institute website. http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf. Accessed May 21, 2013.
13. Diagnosis and classification of diabetes mellitus 2010. Diabetes Care. 33(Suppl 1):S62-S69.
14. Giustina A, Chanson P, Bronstein MD, et al. Aconsensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95:3141-3148.
15. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94:1509-1517.
16. Murray RD, Kim K, Ren SG, Chelly M, Umehara Y, Melmed S. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest. 2004;114:349-356. (Pubitemid 39071607)
17. Pokrajac A, Frystyk J, Flyvbjerg A, Trainer PJ. Pituitary-independent effect of octreotide on IGF1 generation. Eur J Endocrinol. 2009;160:543-548.
18. Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab. 2003;88:3090-3098. (Pubitemid 36877477)
19. Fløgstad AK, Halse J, Bakke S, et al. Sandostatin LAR in acromegalic patients: long-term treatment. J Clin Endocrinol Metab. 1997;82:23-28. (Pubitemid 27021264)
20. Lancranjan I, Bruns C, Grass P, et al. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism. 1996;45:67-71.
21. Lancranjan I, Atkinson AB. Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group. Pituitary. 1999;1:105-114.
22. Fleseriu M. Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary. 2011;14:184-193.
23. Petersenn S, Bollerslev J, Arafat AM, et al. Pasireotide LAR shows efficacy in patients with acromegaly: interim results from a randomized, multicenter, pharmacokinetic, pharmacodynamic, Phase I study. In: Program of the 90th Annual Meeting of The Endocrine Society; June 15-18, 2008; San Francisco, CA. Abstract OR41-5.
24. Hu K, Zhang Y, Jung J, Buchelt A, Wang Y, Petersenn S. Pasireotide (SOM230) provides biochemical control in patients with active acromegaly: pharmacokinetic/pharmacodynamic (PK/PD) results from a randomized, multicenter, Phase II trial. In: Program of the 91st Annual Meeting of The Endocrine Society; June 10-13, 2009; Washington, DC. Abstract P3-677.
25. Petersenn S, Unger N, Hu K, et al. Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers. J Clin Pharmacol. 2012;52:1017-1027.
26. Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013;98:3446-3453.
27. Breitschaft A, Hu K, Hermosillo Reséndiz K, Darstein C, Golor G. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study [published online December 25, 2013]. Diabetes Res Clin Pract. doi:10.1016/j.diabres.2013.12.011.